ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "hypertension"

  • Abstract Number: 2294 • 2016 ACR/ARHP Annual Meeting

    Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production

    Lieke E.J.M. Scheepers1,2, A. Boonen1,2, P.C. Dagnelie2,3,4, M.T. Schram3,5, C.J.H, van der Kallen3,5, R.M.A. Henry3,5, A.A. Kroon3,5, C.D.A. Stehouwer3,6 and I.C.W. Arts3,4,7, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, 2CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 3CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 4Department of Epidemiology, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 5Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, 6Internal Medicine, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, 7MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands

    Background/Purpose: Blood pressure and hypertension are associated with uric acid, the end product of purine catabolism, but the underlying mechanism remainds unclear. During the final…
  • Abstract Number: 2357 • 2016 ACR/ARHP Annual Meeting

    Topical Application of Aceclofenac Might NOT Produce a Significant Increase of Blood Pressure in Osteoarthritic Patients – a Continuous Automated Blood Pressure Monitor Study

    Marius Trandafir1, Ruxandra Ionescu2, Denisa Predeteanu3, Alma Nicu1, MIHAI ABOBULUI4, Andra Rodica Balanescu5, Violeta Bojinca6,7, Daniela Opris3, Violeta Vlad8 and Florian Berghea5,9, 1Sf Maria Hospital, Bucharest, Romania, 2Department of Internal Medicine and Rheumatology, University of Medicine and Pharmacy “Carol Davila”, “, Bucharest, Romania, 3University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 4RCRD, BUCHAREST, Romania, 5Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 6Internal Medicine and Rheumatology Department,, Carol Davila University of Medicine and Pharmacy,, Bucuresti, Romania, 7Sf. Maria Hospital, Bucharest, Romania, 8RCRD Research Center, Bucharest, Romania, 9Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

    Background/Purpose:  Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in Osteoarthritic patients for their anti-inflammatory and pain-killer proprieties. Various reports suggest an increase in blood pressure…
  • Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting

    Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis

    Ani John1, Angela Witt Prehn2, Hebatullah Tawfik2, George W. Reed3 and Joel Kremer4, 1School of Health Sciences, Walden University, Minneapolis, CA, 2School of Health Sciences, Walden University, Minneapolis, MN, 3Corrona, LLC, Southborough, MA, 4The Center for Rheumatology, Albany Medical College, Albany, NY

    Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…
  • Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

    Rishi J. Desai1, Daniel H. Solomon2, Sebastian Schneeweiss3, Goodarz Danaei4, Katherine Liao5 and Seoyoung C. Kim6, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Harvard School of Public Health, Boston, MA, 5Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 6Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
  • Abstract Number: 1498 • 2015 ACR/ARHP Annual Meeting

    Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology

    Edmond Ramly1, Diane Lauver2 and Christie M. Bartels3, 1Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, 2University of Wisconsin-Madison School of Nursing, Madison, WI, 3Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI

    Background/Purpose: Despite routine blood pressure (BP) measurement by clinic staff, we reported that rheumatologists discussed elevated BPs in <1/3 of visits leading to missed opportunities…
  • Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting

    EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update

    Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
  • Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting

    Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients

    Brian LaMoreaux1, Alexa Meara2 and Wael N. Jarjour3, 1Rheumatology, The Ohio State University, Columbus, OH, 2Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, 3Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population.  The main cause of mortality among RA patients…
  • Abstract Number: 1874 • 2015 ACR/ARHP Annual Meeting

    Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension

    Helen Jin1, John T. Granton2, John Thenganatt3, Jakov Moric3, Ambika Gupta1, Amie T. Kron1, Cathy Chau1 and Sindhu R. Johnson1, 1Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, 2Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, 3Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Poorer health outcomes for persons with chronic diseases have been reported in association with lower socioeconomic status (SES). No such evaluation exists for patients…
  • Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting

    Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease

    Natalie K. Kozij1, John T. Granton2, Philip E. Silkoff3, John Thenganatt4, Shobha Chakravorty4 and Sindhu R. Johnson5, 1Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, 2Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, 3Medicine, Temple University, Philadelphia, PA, 4Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, 5Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
  • Abstract Number: 2079 • 2015 ACR/ARHP Annual Meeting

    Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression

    Maite Castro1, Eduardo Ferreira Borba1, Michelle Lopes1, Sandra G. Pasoto2, Eloisa Bonfá1 and Luciana Seguro2, 1Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Hypertension and persistent proteinuria are risk factors for renal disease progression and are associated with high salt intake, poor adherence to medication and smoking.…
  • Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting

    Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study

    Jeewoong Choi1, Na Lu2, Yuqing Zhang3, Sharan K. Rai4, Gary C. Curhan5 and Hyon K. Choi2, 1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, 2Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3BUSM, Boston, MA, 4Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 5Renal Division, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
  • Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting

    Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease

    Sylvie Perreault1, Javier Nuevo2, Scott Baumgartner3 and Robert Morlock4, 1University of Montreal, Montreal, QC, Canada, 2AstraZeneca, Madrid, Spain, Madrid, Spain, 3Ardea Biosciences, Inc., San Diego, CA, 44939 Directors Place, Ardea Biosciences, Inc., San Diego, CA

    Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
  • Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting

    Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program

    Jeffrey R. Curtis1, Ara Dikranian2, Alan Mendelsohn3, Koshika Soma4, Haiyun Fan3 and Chudy Nduaka3, 1University of Alabama at Birmingham, Birmingham, AL, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
  • Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting

    Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort

    Matthew R. Lammi1, Lesley Ann Saketkoo2, Stephen C. Mathai3, Robyn T. Domsic4, Christine M. Bojanowski5, Virginia D. Steen6, Daniel E. Furst7 and Pharos Investigators8, 1Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 3Medicine, Johns Hopkins University, Baltimore, MD, 4Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 5Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, 6Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 7University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 8Georgetown University Medical Center, Washington, DC

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc).  Although medications have improved their prognosis, optimal therapy remains undefined.…
  • Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting

    Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function

    Ashira Blazer1, H. Michael Belmont2, Robert Clancy3, Peter M. Izmirly4 and Jill P. Buyon5, 1Division of Rheumatology, NYU School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY, 3Rheumatology, NYU Medical Center, New York, NY, 4Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology